Estimated read time: Less than a minute
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
WASHINGTON (AP) — The Supreme Court won't hear an appeal from a Johnson & Johnson subsidiary assessed more than $124 million in penalties for deceptive marketing of an anti-psychotic drug.
The justices on Monday let stand a lower court ruling that said Janssen Pharmaceuticals, Inc. should pay the penalties for violations of South Carolina law.
In 2011, a state trial court ordered the drug maker to pay $327 million, saying Janssen broke the law by downplaying to doctors the links between diabetes and Risperdal and by improperly claiming the drug was safer than competing medications. South Carolina's supreme court reduced the penalty because of the state's three-year statute of limitations on such cases.
The company claimed the penalty was excessive and that state law was pre-empted by federal drug laws.
Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
